Cns Pharmaceuticals Inc (NASDAQ: CNSP) has seen a decline in its stock price by -8.89 in relation to its previous close of 3.71. However, the company has experienced a 10.46% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-02-26 that Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided an update on its current cash position and discussed the completion of its recent initiative to maintain its listing on the NASDAQ Capital Market (“NASDAQ”). “As we kick off 2025, the Company has never been fundamentally stronger.
Is It Worth Investing in Cns Pharmaceuticals Inc (NASDAQ: CNSP) Right Now?
CNSP has 36-month beta value of 0.63. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CNSP is 2.72M, and currently, short sellers hold a 9.87% ratio of that float. The average trading volume of CNSP on March 25, 2025 was 635.91K shares.
CNSP’s Market Performance
CNSP stock saw an increase of 10.46% in the past week, with a monthly gain of 4.64% and a quarterly increase of -39.64%. The volatility ratio for the week is 17.29%, and the volatility levels for the last 30 days are 14.75% for Cns Pharmaceuticals Inc (CNSP). The simple moving average for the past 20 days is 19.41% for CNSP’s stock, with a -85.76% simple moving average for the past 200 days.
Analysts’ Opinion of CNSP
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CNSP reach a price target of $11. The rating they have provided for CNSP stocks is “Buy” according to the report published on August 24th, 2020.
CNSP Trading at -18.87% from the 50-Day Moving Average
After a stumble in the market that brought CNSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.65% of loss for the given period.
Volatility was left at 14.75%, however, over the last 30 days, the volatility rate increased by 17.29%, as shares surge +17.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.72% lower at present.
During the last 5 trading sessions, CNSP rose by +10.46%, which changed the moving average for the period of 200-days by -98.95% in comparison to the 20-day moving average, which settled at $2.83. In addition, Cns Pharmaceuticals Inc saw -43.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CNSP
Current profitability levels for the company are sitting at:
- -2684.89 for the present operating margin
- 0.6 for the gross margin
The net margin for Cns Pharmaceuticals Inc stands at -2681.03. The total capital return value is set at -5.1. Equity return is now at value -2116.75, with -350.34 for asset returns.
Based on Cns Pharmaceuticals Inc (CNSP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -454.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1052.64.
Currently, EBITDA for the company is -18.86 million with net debt to EBITDA at 0.41. When we switch over and look at the enterprise to sales, we see a ratio of 364.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.81.
Conclusion
To put it simply, Cns Pharmaceuticals Inc (CNSP) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
